Black Diamond Therapeutics (BDTX) insider buying

Healthcare · Biotechnology · Market cap $101M

4 open-market purchases of BDTX by Black Diamond Therapeutics's executives and directors since June 2023, worth $20M in total, from SEC Form 4 filings.

The most recent: Growth N V Biotech bought $936,000 on October 17, 2023.

The biggest buyer over the period is Growth N V Biotech: 3 purchases, $15M.

By year

YearPurchasesValue
20234$20M

Biggest buyers

InsiderBuysValue
Growth N V Biotech
3$15M
Ali Behbahani
1$5M

Every purchase

Newest first. From SEC Form 4 filings. Insider buying across the market.

DateInsiderSharesPriceValueFiling
Oct 17, 2023 Growth N V Biotech
 400,000$2.34$936,000 Form 4
Jul 5, 2023 Ali Behbahani
 1,000,000$5.00$5M Form 4
Jun 30, 2023 Growth N V Biotech
 1,000,000$5.00$5M Form 4
Jun 27, 2023 Growth N V Biotech
 1,740,000$5.49$10M Form 4
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for BDTX.
Open BDTX in Investingly

Questions

Are Black Diamond Therapeutics insiders buying the stock?

4 open-market purchases of BDTX by Black Diamond Therapeutics's executives and directors since June 2023, worth $20M in total, from SEC Form 4 filings. The most recent: Growth N V Biotech bought $936,000 on October 17, 2023.

What counts as insider buying here?

Open-market purchases (Form 4 code P) by officers and directors. Option exercises, grants and purchases by 10% owners are left out.

From Black Diamond Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.